<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134626</url>
  </required_header>
  <id_info>
    <org_study_id>simvhp01</org_study_id>
    <nct_id>NCT02134626</nct_id>
  </id_info>
  <brief_title>Simvastatin Effect on Portal Hypertension</brief_title>
  <official_title>Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ItÂ´s a clinical research of the effects in portal hypertension caused by simvastatin. We are&#xD;
      going to use the hepatic venous pressure gradient(HVPG) measurement and the azygos flow at&#xD;
      echoendoscopy to evaluate the benefits of the drug. Preliminary studies demonstrated that&#xD;
      simvastatin can lower portal pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The simvastatin can target the liver enhancing nitric oxide intra-hepatic and lowering&#xD;
      resistance that may be responsible for most of cirrhosis complications. Indeed, the potential&#xD;
      use of this drug may ameliorate the HVPG and azygos flow. Portal hypertension is responsible&#xD;
      for most of the cases of death in cirrhosis. The esophageal varices, ascites and hepatorenal&#xD;
      syndrome are the most harmful consequences of cirrhosis that should be prevented. In that&#xD;
      way, simvastatin appears as a promising therapy.The study will include two groups of patients&#xD;
      using aleatory randomization and one group will receive simvastatin while the other will&#xD;
      receive placebo blindly. At the start and at the end of the study the patients will be&#xD;
      submitted to HVPG measurement and azygous vein flow measure.&#xD;
&#xD;
      The endpoints will be the normalization of HVPG or lower significantly(20% or more.&#xD;
&#xD;
      The patients will be followed for 6 months after the end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic venous pressure gradient (HVPG) in mmHg units</measure>
    <time_frame>3 months</time_frame>
    <description>Positive results consist of reduction of the HVPG to values equal or less than 12 mmHg or 20% lower than the first measure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Portal Hypertension</condition>
  <condition>Esophageal Varices</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: Simvastatin 40mg / pill, one pill once a day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2: Placebo one pill once a day for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40mg / pill, one pill orally once a day for three months</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Portal hypertension: esophageal varices, ascites, splenomegaly or hepatorenal&#xD;
             syndrome.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh C decompensated or encephalopathy&#xD;
&#xD;
          -  Malignancy except basocellular cancer&#xD;
&#xD;
          -  Hepatocarcinoma&#xD;
&#xD;
          -  Anti-viral therapy&#xD;
&#xD;
          -  HIV&#xD;
&#xD;
          -  Prevention of digestive hemorrhage with band ligation or sclerotherapy for the last 6&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priscila Pollo-Flores, MD, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Rio de Janeiro - UFRJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Guilherme Rezende</investigator_full_name>
    <investigator_title>Associate Professor of the Medical Faculty</investigator_title>
  </responsible_party>
  <keyword>Portal Hypertension</keyword>
  <keyword>Hepatic Venous Pressure Gradient</keyword>
  <keyword>Esophageal Varices</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>HVPG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

